TRB Middle East-Africa

TRB Chemedica is a Swiss-based medium-sized pharmaceutical company that specializes in the research, development, and manufacturing of innovative products in the fields of rheumatology, ophthalmology, and neurology. The company is particularly well-known for its expertise in hyaluronic acid-based treatments, marketing flagship brands such as OSTENIL for osteoarthritis and VISMED for dry eye syndrome. TRB Chemedica Middle East-Africa serves as the regional hub for distributing and managing these specialized therapies across the MEA region. The company maintains a vertically integrated model, overseeing the entire process from initial research to global commercialization.